PSquared Asset Management AG Acquires New Holdings in Structure Therapeutics Inc. Sponsored ADR $GPCR

PSquared Asset Management AG acquired a new position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 35,000 shares of the company’s stock, valued at approximately $1,687,000. Structure Therapeutics makes up about 0.6% of PSquared Asset Management AG’s holdings, making the stock its 15th largest holding.

Other large investors also recently bought and sold shares of the company. CWM LLC lifted its holdings in Structure Therapeutics by 35.2% during the fourth quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after buying an additional 125 shares during the period. HighTower Advisors LLC increased its holdings in shares of Structure Therapeutics by 3.6% in the 4th quarter. HighTower Advisors LLC now owns 9,320 shares of the company’s stock valued at $648,000 after acquiring an additional 320 shares during the period. State of Wyoming increased its holdings in shares of Structure Therapeutics by 29.7% in the 4th quarter. State of Wyoming now owns 1,761 shares of the company’s stock valued at $122,000 after acquiring an additional 403 shares during the period. China Universal Asset Management Co. Ltd. raised its position in shares of Structure Therapeutics by 4.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,888 shares of the company’s stock worth $757,000 after acquiring an additional 444 shares in the last quarter. Finally, Assetmark Inc. raised its position in shares of Structure Therapeutics by 21.4% in the 1st quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock worth $123,000 after acquiring an additional 449 shares in the last quarter. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Trading Up 0.8%

Shares of GPCR stock opened at $50.80 on Friday. The business’s fifty day simple moving average is $45.21 and its 200-day simple moving average is $55.90. The company has a market cap of $3.61 billion, a PE ratio of -58.39 and a beta of -1.50. Structure Therapeutics Inc. Sponsored ADR has a 12-month low of $15.80 and a 12-month high of $94.90.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.04. On average, equities analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -1.64 earnings per share for the current year.

Wall Street Analyst Weigh In

GPCR has been the subject of a number of analyst reports. Canaccord Genuity Group assumed coverage on Structure Therapeutics in a research note on Monday, April 27th. They set a “buy” rating and a $101.00 price objective for the company. HC Wainwright cut their target price on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a research note on Thursday, June 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Friday, July 17th. Wolfe Research initiated coverage on shares of Structure Therapeutics in a research report on Thursday, March 26th. They set a “peer perform” rating for the company. Finally, Wall Street Zen cut shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Structure Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $110.55.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.